

10/516,292 03/28/2010



=> screen 1947 AND 1992 AND 2004 AND 1970 AND 1839

L1 SCREEN CREATED

=>

Uploading C:\Program Files\STNEXP\Queries\10516292.str

10/516,292 03/28/2010



chain nodes :
7 8 9 17 18 19 20 21 24 25 26 27 29
ring nodes :
1 2 3 4 5 6 10 11 12 13 14 15

10/516,292 03/28/2010

chain bonds :
1-29 4-17 5-7 7-8 7-9 9-11 17-18 19-20 20-21 24-25 24-26 24-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15
exact/norm bonds :
1-29 4-17 7-8 7-9 9-11 17-18 20-21
exact bonds :
5-7 19-20 24-25 24-26 24-27
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

G1:H, [*1]

Hydrogen count :
9:= exact 1 14:= exact 1
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 17:CLASS 18:CLASS 19:CLASS 20:CLASS
21:CLASS 24:CLASS
25:CLASS 26:CLASS 27:CLASS 28:Atom 29:CLASS

L2 STRUCTURE UPLOADED

=> que L2 AND L1

L3 QUE L2 AND L1

=> s l3 sss sam
SAMPLE SEARCH INITIATED 19:10:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 783 TO ITERATE

100.0% PROCESSED 783 ITERATIONS 19 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 13982 TO 17338
PROJECTED ANSWERS: 119 TO 641

L4 19 SEA SSS SAM L2 AND L1

=> s l3 sss full
FULL SEARCH INITIATED 19:10:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 16514 TO ITERATE

100.0% PROCESSED 16514 ITERATIONS 407 ANSWERS
SEARCH TIME: 00.00.01

L5 407 SEA SSS FUL L2 AND L1

=> file caplus

=> s l5
L6 191 L5

10/516,292 03/28/2010

=> s cancer or neoplasm or ?tumor or (tumor OR "Tumor, plant") or melanoma or leukemia or myeloma or lymphoma or rhabdomyoma or ?sarcoma or ?blastoma

448675 CANCER
65850 CANCERS
464879 CANCER
(CANCER OR CANCERS)
587717 NEOPLASM
38720 NEOPLASMS
605087 NEOPLASM
(NEOPLASM OR NEOPLASMS)
720847 ?TUMOR
537770 TUMOR
193641 TUMORS
596668 TUMOR
(TUMOR OR TUMORS)
537770 "TUMOR"
193641 "TUMORS"
596668 "TUMOR"
("TUMOR" OR "TUMORS")
996713 "PLANT"
535385 "PLANTS"
1214068 "PLANT"
("PLANT" OR "PLANTS")
1313 "TUMOR, PLANT"
("TUMOR" (W) "PLANT")
45358 MELANOMA
4373 MELANOMAS
19 MELANOMATA
45949 MELANOMA
(MELANOMA OR MELANOMAS OR MELANOMATA)
130116 LEUKEMIA
8287 LEUKEMIAS
131705 LEUKEMIA
(LEUKEMIA OR LEUKEMIAS)
24816 MYELOMA
656 MYELOMAS
25039 MYELOMA
(MYELOMA OR MYELOMAS)
49720 LYMPHOMA
10802 LYMPHOMAS
52011 LYMPHOMA
(LYMPHOMA OR LYMPHOMAS)
55 RHABDOMYOMA
20 RHABDOMYOMAS
63 RHABDOMYOMA
(RHABDOMYOMA OR RHABDOMYOMAS)
59159 ?SARCOMA
43065 ?BLASTOMA

L7 1167562 CANCER OR NEOPLASM OR ?TUMOR OR (TUMOR OR "TUMOR, PLANT") OR
MELANOMA OR LEUKEMIA OR MYELOMA OR LYMPHOMA OR RHABDOMYOMA OR
?SARCOMA OR ?BLASTOMA

=> s 16 and 17

L8 31 L6 AND L7

=> s 18 and py<2005

25157644 PY<2005

L9 11 L8 AND PY<2005

10/516,292 03/28/2010

=> d ibib abs hitstr hitind 1-11


L9 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:991336 CAPLUS <<LOGINID::20100328>>
DOCUMENT NUMBER: 140:42202
TITLE: Preparation of hydroxybenzamide,
naphthalenecarboxamide, and
hydroxyheterocyclecarboxamide derivatives as
anticancer agents
INVENTOR(S): Muto, Susumu; Itai, Akiko
PATENT ASSIGNEE(S): Institute of Medicinal Molecular Design. Inc., Japan
SOURCE: PCT Int. Appl., 265 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003103655	A1	20031218	WO 2003-JP7121	20030605 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2488974	A1	20031218	CA 2003-2488974	20030605 <--
AU 2003242108	A1	20031222	AU 2003-242108	20030605 <--
AU 2003242108	B2	20080911		
EP 1535610	A1	20050601	EP 2003-730832	20030605
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1658856	A	20050824	CN 2003-813312	20030605
CN 100506221	C	20090701		
US 20060014811	A1	20060119	US 2005-516292	20050705
PRIORITY APPLN. INFO.:			JP 2002-168332	A 20020610
			WO 2003-JP7121	W 20030605

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 140:42202

GI



AB Disclosed are drugs for the prevention and/or treatment of cancer

, which contain as the active ingredient substances selected from the group consisting of compds. represented by the general formula (I), pharmacol. acceptable salts thereof, and hydrates and solvates of both [wherein A is hydrogen or acetyl; E is 2,5- or 3,5-disubstituted Ph or an optionally substituted monocyclic or fused-polycyclic heteroaryl group (exclusive of (1) fused -polycyclic heteroaryl whose benzene ring is bonded directly to the -CONH- group, (2) unsubstituted thiazol-2-yl, and (3) unsubstituted benzothiazol-2-yl); and Z is arene which may have a substituent in addition to the groups represented by the general formulas: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above) or heteroarene which may have a substituent in addition to the groups represented by the general formulas: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above)]. The compds. I including N-phenylhydroxybenzamide (N-phenylsalicylamide), N-phenylhydroxynaphthalenecarboxamide, N-heterocyclylsalicylamide, N-phenylpyridinecarboxamide, N-phenylhydroxythiophenecarboxamide, N-phenylquinoxalinecarboxamide, and N-phenylindolecarboxamide derivs. in vitro inhibited the proliferation of Jurkat, MIA PACA-2, RD, HepG2, and A549 human cancer cells. N-[3,5-bis(trifluoromethyl)phenyl]-4-chloro-2-hydroxybenzamide in vitro inhibited the proliferation of B16 melanoma, HT-1080 fibrosarcoma, NB-1 neuroblastoma, and HMC-1-8 breast cancer cells and in vivo metastasis of B16 melanoma in mice.

L9 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:991335 CAPLUS <<LOGINID::20100328>>

DOCUMENT NUMBER: 140:42201

TITLE: Preparation of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclecarboxamide derivatives as transcription factor NF- κ B activation inhibitors

INVENTOR(S): Muto, Susumu; Itai, Akiko

PATENT ASSIGNEE(S): Institute of Medicinal Molecular Design. Inc., Japan

SOURCE: PCT Int. Appl., 286 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003103654	A1	20031218	WO 2003-JP7119	20030605 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2489091	A1	20031218	CA 2003-2489091	20030605 <--
AU 2003242098	A1	20031222	AU 2003-242098	20030605 <--
AU 2003242098	B2	20081120		
EP 1535609	A1	20050601	EP 2003-730830	20030605
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

10/516,292 03/28/2010

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
CN 1658857 A 20050824 CN 2003-813313 20030605
CN 100464742 C 20090304
US 20060089395 A1 20060427 US 2005-516294 20050912
US 20080311074 A1 20081218 US 2008-81162 20080411
PRIORITY APPLN. INFO.: JP 2002-168924 A 20020610
WO 2003-JP7119 W 20030605
US 2005-516294 A3 20050912
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 140:42201
GI



AB Disclosed are drugs having an inhibitory activity against transcription factor NF- κ B activation, which contain as the active ingredient substances selected from the group consisting of compds. represented by the general formula (I), pharmacol. acceptable salts thereof, and hydrates and solvates of both [wherein A is hydrogen or acetyl; E is 2,5- or 3,5-disubstituted Ph or an optionally substituted monocyclic or fused-polycyclic heteroaryl group (exclusive of (1) fused -polycyclic heteroaryl whose benzene ring is bonded directly to the -CONH- group, (2) unsubstituted thiazol-2-yl, and (3) unsubstituted benzothiazol-2-yl); and Z is arene which may have a substituent in addition to the groups represented by the general formulas: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above) or heteroarene which may have a substituent in addition to the groups represented by the general formulas: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above)]. Also disclosed are (1) inhibitors against production and release of inflammatory mediators and immunosuppressants and (2) drugs for prevention and/or treatment of chronic articular rheumatism. The compds. I including N-phenylhydroxybenzamide (N-phenylsalicylamide), N-phenylhydroxynaphthalenecarboxamide, N-heterocyclisalicylamide, N-phenylpyridinecarboxamide, N-phenylhydroxythiophenecarboxamide, N-phenylquinoxalinecarboxamide, and N-phenylindolecarboxamide derivs. exhibited the inhibition of (1) TNF- α -stimulated activation of NF- κ B (2) TNF- α -stimulated production of IL-6, IL-8, and PGE2 in human synoviocyte (RA-pos.) cells, (3) collagen-induced inflammation in mice, (4) myocardial ischemic reperfusion disorder in rats, and (5) proliferation of smooth muscle cells of normal coronary artery blood vessel. Some com. available compds. were selected as NF- κ B inhibitors (ligands) by virtual screening using a three-dimensional database automated retrieval software based on a protein structure of NF- κ B. The activity of the selected compds. were confirmed by reporter assay for inhibition of TNF- α -stimulated activation of NF- κ B and an assay for inhibition of NF- α -stimulated production of inflammatory mediators.

IT 906-38-7P 978-62-1P 982-71-8P

10/516,292 03/28/2010


439144-26-0P 439144-29-3P 439144-43-1P
439144-46-4P 439144-53-3P 439144-65-7P
439144-78-2P 634185-07-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclecarboxamide derivs. as transcription factor NF- κ B activation inhibitors)


RN 906-38-7 CAPLUS

CN Benzamide, N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-iodo- (CA INDEX NAME)



RN 978-62-1 CAPLUS

CN Benzamide, N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxy- (CA INDEX NAME)



L9 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:754333 CAPLUS <<LOGINID::20100328>>

DOCUMENT NUMBER: 137:279214

TITLE: Preparation of benzoic acid derivatives as nuclear factor κ B inhibitors

INVENTOR(S): Suzuki, Kenji; Nunokawa, Youichi; Ogou, Naohisa

PATENT ASSIGNEE(S): Suntory Limited, Japan; Suntory Biomedical Research Limited

SOURCE: PCT Int. Appl., 243 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076918	A1	20021003	WO 2002-JP3017	20020327 <--
W: BR, CA, CN, HU, JP, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2410816	A1	20021003	CA 2002-2410816	20020327 <--
BR 2002004678	A	20030429	BR 2002-4678	20020327 <--
EP 1314712	A1	20030528	EP 2002-708696	20020327 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
HU 2003002479	A2	20031128	HU 2003-2479	20020327 <--
US 20040122244	A1	20040624	US 2002-296810	20021127 <--
US 7064124	B2	20060620		
PRIORITY APPLN. INFO.:			JP 2001-91003	A 20010327
			WO 2002-JP3017	W 20020327
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 137:279214				
GI				




AB The title compds. I [R1 = (1,4-benzoquinon-2-yl)methyl (with substituents selected from H, alkyl, etc.) (generic structure given), etc.; R2 = H, (un)substituted alkyl, etc.; X = carboxyl (which may esterified or amidated)] are prepared In an in vitro test for nuclear factor κ B inhibiting activity, N-[5-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-yl)methyl-2-hydroxybenzoyl]-4-aminobenzoic acid Et ester showed IC50 value of 3 μ g/mL.

IT 464214-65-1P 464215-03-0P 464215-09-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of benzoic acid derivs. as nuclear factor κ B inhibitors)

RN 464214-65-1 CAPLUS


CN Benzamide, 2-(acetyloxy)-N-[3,5-bis(trifluoromethyl)phenyl]-5-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]- (CA INDEX NAME)




10/516,292 03/28/2010

RN 464215-03-0 CAPLUS

CN Benzamide, 2-(acetyloxy)-5-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



CN Benzamide, N-[3,5-bis(trifluoromethyl)phenyl]-5-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-2-hydroxy- (CA INDEX NAME)



RN 464215-04-1 CAPLUS

L9 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:487387 CAPLUS <<LOGINID::20100328>>

DOCUMENT NUMBER: 137:63257

TITLE: Preparation of benzamides as inhibitors of production and release of inflammatory cytokines

INVENTOR(S): Muto, Susumu; Nagano, Tatsuo; Saotome, Tomomi; Itai, Akiko

PATENT ASSIGNEE(S): Institute of Medicinal Molecular Design Inc., Japan

SOURCE: PCT Int. Appl., 313 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2002049632	A1	20020627	WO 2001-JP11084	20011218 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,			

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2431083 A1 20020627 CA 2001-2431083 20011218 <--
 AU 2002022683 A 20020701 AU 2002-22683 20011218 <--
 EP 1352650 A1 20031015 EP 2001-271124 20011218 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 AU 2002222683 B2 20060921 AU 2002-222683 20011218
 EP 1844766 A2 20071017 EP 2007-15076 20011218
 EP 1844766 A3 20090429
 R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,
 NL, PT, SE, TR, AL, LT, LV, MK, RO, SI
 EP 1847263 A2 20071024 EP 2007-15427 20011218
 EP 1847263 A3 20090826
 R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,
 NL, PT, SE, TR, AL, LT, LV, MK, RO, SI
 CN 101125138 A 20080220 CN 2007-10140060 20011218
 CN 100370975 C 20080227 CN 2001-822716 20011218
 JP 4224566 B2 20090218 JP 2002-550974 20011218
 KR 2009090406 A 20090825 KR 2009-716971 20011218
 US 20040259877 A1 20041223 US 2004-433619 20040219 <--
 HK 1063433 A1 20080905 HK 2004-106223 20040819
 US 20080249071 A1 20081009 US 2007-835997 20070808
 US 20090192122 A2 20090730
 US 20080318956 A1 20081225 US 2007-835978 20070808
 PRIORITY APPLN. INFO.: JP 2000-383202 A 20001218
 CN 2001-822716 A3 20011218
 EP 2001-271124 A3 20011218
 WO 2001-JP11084 W 20011218
 KR 2003-708036 A3 20030616
 US 2004-433619 A3 20040219
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 137:63257
 GI




AB The title compds. I (wherein X is a connecting group; A is hydrogen or acetyl; E is aryl or heteroaryl; and Z is arene or heteroarene) are prepared In an in vitro test using cells, 5-chloro-2-hydroxy-N-(4-methoxynaphthalen-2-yl)benzamide at 1 μ g/mL gave 95.1% inhibition of NF- κ B activation.

L9 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1992:143846 CAPLUS <<LOGINID::20100328>>
 DOCUMENT NUMBER: 116:143846
 ORIGINAL REFERENCE NO.: 116:24085a,24088a
 TITLE: Tumor promoter inhibitors containing nitrophenylglucinol derivatives

10/516,292 03/28/2010

INVENTOR(S): Honda, Ichiro; Tokuda, Harukuni; Nishino, Hoyoku;
Yoshida, Shigeo; Kozuka, Mutsuo; Yoneyama, Koichi
PATENT ASSIGNEE(S): Japan Tobacco, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
JP 03271222	A	19911203	JP 1990-69852	19900322 <--
PRIORITY APPLN. INFO.:			JP 1990-69852	19900322
OTHER SOURCE(S):	MARPAT 116:143846			
GI				



AB Antitumor agents which inhibit tumor promoters contain nitrophenylglucinol derivs. I [R = C1-18 straight-chain alkyl, cyclohexyl, substituted Ph, phenylalkyl (containing C1-4 alkyl)] or II (R = C1-10 straight-chain alkyl). I (R = Me) at 100-fold dilution inhibited 12-O-tetradecanoylphorbol-13-acetate (III)-induced production of Epstein-Barr virus early antigens by 92.35%. Topical application of I to mice inhibited tumors induced by DMBA and III.

L9 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1991:597735 CAPLUS <<LOGINID::20100328>>

DOCUMENT NUMBER: 115:197735

ORIGINAL REFERENCE NO.: 115:33489a,33492a

TITLE: Inhibitory effects of
3-nitro-2,4,6-trihydroxybenzamides on Epstein-Barr
virus early antigen induction

AUTHOR(S): Honda, Ichiro; Tokuda, H.; Kozuka, M.; Yoneyama, K.;
Nishino, H.; Iwashima, A.; Shibagaki, M.; Noma, M.;
Takahashi, N.; Yoshida, S.

CORPORATE SOURCE: Life Sci. Res. Lab., Japan Tob. Inc., Yokohama, 227,
Japan


SOURCE: Cancer Letters (Shannon, Ireland) (1991),
59(2), 83-8

CODEN: CALEDQ; ISSN: 0304-3835

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Inhibitory effects of a series of 3-nitro-2,4,6-trihydroxybenzamides (I; R = alkyl, benzyl, substituted Ph, etc.) of Epstein-Barr virus early antigen (EBV-EA) induction were examined using Raji cells. Some of the tested compds. showed highly inhibitory activity, the N-octyl amide derivative being the most active among them. These results suggest the possibility that 3-nitro-2,4,6-trihydroxybenzamides might be listed as novel inhibitors of tumor promotion.

IT 129235-56-9 129235-57-0

RL: BIOL (Biological study)

(Epstein-Barr virus early antigen induction inhibition by, structure in relation to)

RN 129235-56-9 CAPLUS

CN Benzamide, 2,4,6-trihydroxy-3-nitro-N-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)

